INTRODUCTION: Statins, particularly rosuvastatin, have recently become relevant in the setting of venous thrombosis. The objective of this study was to study the non-lipid lowering effects of rosuvastatin in venous thrombosis in mice with hyperlipidemia. MATERIALS AND METHODS: An inferior vena cava ligation model of venous thrombosis in mice was utilized. Saline or 5mg/kg of rosuvastatin was administered by gavage 48hs previous to thrombosis. Blood, the inferior vena cava, thrombus, and liver were harvested 3, 6hours, and 2days post-thrombosis. Thrombus weight, inflammatory markers, and plasminogen activator inhibitor-1 expression and plasma levels were measured. Also, neutrophil migration to the IVC was assessed. RESULTS: Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall. CONCLUSIONS: This work supports the beneficial effects of rosuvastatin on venous thrombosis in mice with hyperlipidemia, due to its non-lipid lowering effects.
INTRODUCTION: Statins, particularly rosuvastatin, have recently become relevant in the setting of venous thrombosis. The objective of this study was to study the non-lipid lowering effects of rosuvastatin in venous thrombosis in mice with hyperlipidemia. MATERIALS AND METHODS: An inferior vena cava ligation model of venous thrombosis in mice was utilized. Saline or 5mg/kg of rosuvastatin was administered by gavage 48hs previous to thrombosis. Blood, the inferior vena cava, thrombus, and liver were harvested 3, 6hours, and 2days post-thrombosis. Thrombus weight, inflammatory markers, and plasminogen activator inhibitor-1 expression and plasma levels were measured. Also, neutrophil migration to the IVC was assessed. RESULTS:Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall. CONCLUSIONS: This work supports the beneficial effects of rosuvastatin on venous thrombosis in mice with hyperlipidemia, due to its non-lipid lowering effects.
Authors: Florian Bea; Erwin Blessing; Brian Bennett; Michael Levitz; Elizabeth P Wallace; Michael E Rosenfeld Journal: Arterioscler Thromb Vasc Biol Date: 2002-11-01 Impact factor: 8.311
Authors: B K Arendt; A Velazquez-Dones; R C Tschumper; K G Howell; S M Ansell; T E Witzig; D F Jelinek Journal: Leukemia Date: 2002-10 Impact factor: 11.528
Authors: P Escudero; A Navarro; C Ferrando; E Furio; H Gonzalez-Navarro; M Juez; M J Sanz; L Piqueras Journal: Br J Pharmacol Date: 2015-03-26 Impact factor: 8.739
Authors: Pei Yu; Ting Xiong; Christine B Tenedero; Paul Lebeau; Ran Ni; Melissa E MacDonald; Peter L Gross; Richard C Austin; Bernardo L Trigatti Journal: Arterioscler Thromb Vasc Biol Date: 2017-11-21 Impact factor: 8.311
Authors: Elise P DeRoo; Shirley K Wrobleski; Evelyn M Shea; Ramsey K Al-Khalil; Angela E Hawley; Peter K Henke; Daniel D Myers; Thomas W Wakefield; Jose A Diaz Journal: Blood Date: 2014-11-26 Impact factor: 22.113
Authors: Deya Cherpokova; Charlotte C Jouvene; Stephania Libreros; Elise P DeRoo; Long Chu; Xavier de la Rosa; Paul C Norris; Denisa D Wagner; Charles N Serhan Journal: Blood Date: 2019-10-24 Impact factor: 22.113
Authors: Andrea T Obi; Jose A Diaz; Nicole L Ballard-Lipka; Karen J Roelofs; Diana M Farris; Daniel A Lawrence; Peter K Henke; Thomas W Wakefield Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-10-01
Authors: Jose A Diaz; Christine M Alvarado; Shirley K Wrobleski; Dallas W Slack; Angela E Hawley; Diana M Farris; Peter K Henke; Thomas W Wakefield; Daniel D Myers Journal: Thromb Haemost Date: 2013-03-28 Impact factor: 5.249